Modern Oral Rapid Growth
Modern Oral gross sales grew 167% year-over-year to $69M and net sales grew 133% year-over-year to $52M; Modern Oral accounted for 42% of consolidated net sales (up from 21% in Q1 2025).
Upgraded Full‑Year Modern Oral Guidance
Full‑year 2026 Modern Oral gross sales guidance increased to $280M–$300M (was $220M–$240M) and net sales guidance to $210M–$225M (was $180M–$190M); implied midpoint gross revenue growth ~83.7%.
Consolidated Revenue and Profitability
Consolidated sales rose 17% year‑over‑year to $124.3M; gross profit increased 14.6% to $68.3M; adjusted EBITDA was $25.9M (20.8% margin), which exceeded the midpoint of guidance.
Strong Stoker's Segment Performance
Stoker's segment net sales increased 48% year‑over‑year to $88M and now represents ~70% of consolidated net sales; Stoker's gross profit increased 39% to $47M.
Retail Expansion Momentum and Chain Wins
Company expects chain store count to increase ~70% by end of 2026 versus prior year; recent national/regional chain wins and rollout beginning in weeks with stores filling out across the year.
Commercial and Brand Investments
Management is investing heavily in sales force, merchandising and brand building (including a multi‑property TKO partnership with UFC/Zuffa/PBR) and plans total S&M investment of $80M–$105M in 2026 to accelerate awareness and distribution.
Manufacturing and Margin Improvement Plans
Commissioning of Louisville manufacturing is underway to localize production, improve supply control and reduce freight/tariff exposure; management targets Modern Oral margins approaching ~70% at scale by the end of the decade.
Strong Liquidity Position
Ended Q1 with $192.4M cash on hand and management expects to be approximately cash‑flow breakeven for the remainder of the year despite upfront investments.
Zig‑Zag Margin Expansion
Zig‑Zag gross margin improved by 300 basis points to 57.1% year‑over‑year, reflecting better mix and pricing even as sales declined.